Sepsis, Sepsis and Septic Shock, Sepsis at Intensive Care Unit, Sepsis, Septic Shock, Sepsis, Severe, Sepsis, Severe Sepsis and Septic Shock, Sepsis With Acute Organ Dysfunction, Sepsis With Multiple Organ Dysfunction (MOD)
Conditions
Keywords
Sepsis, Transposable Elements, Immune Aging, Mortality, Secondary Infections, Critical Care Medicine (ICU)
Brief summary
The goal of this observational study is to learn about how transposable element levels affect the patient outcomes in sepsis. The main questions it aims to answer is: 1. Do transposable elements prematurely age the immune systems of patients with sepsis? 2. Do transposable elements correlate with increased mortality in patients with sepsis in the ICU? 3. Do transposable elements correlate with increased amount of secondary infections in patients with sepsis in the ICU? Participants will have blood drawn from them but will not be subjected to additional interventions.
Interventions
GENETICRNA and DNA Sequencing
DNA and RNA sequencing will be conducted on both control participants and patients with sepsis who are admitted to the ICU.
Sponsors
University of California, San Francisco
National Cancer Institute (NCI)
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Age 18 or older * Admitted to ICU with sepsis (Sepsis 3 Criteria) * SOFA score of at least 2 at time of enrollment
Exclusion criteria
* Patients on organ transplantation immunosuppression * Patients with preexisting leukopenia * Cancer patients receiving CAR-T therapy * Patients who are under 18 years of age or otherwise deemed pediatric * Patients with an ongoing bleeding diathesis (ie: DIC, hemorrhagic shock) * Patients with a chronic hemoglobin below 7.0 * Patients who, prior to their ICU admission, are blood transfusion dependent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Immune Aging | 6 weeks |
Secondary
| Measure | Time frame |
|---|---|
| Mortality (30-day) | 30 days |
| Secondary Infection | 30 days |
Countries
United States
Contacts
CONTACTAlexendar R Perez, M.D., Ph.D
CONTACTMatthieu Legrand, M.D., Ph.D
PRINCIPAL_INVESTIGATORAlexendar R Perez, M.D., Ph.D
University of California, San Francisco
PRINCIPAL_INVESTIGATORJudith Hellman, M.D.
University of California, San Francisco
PRINCIPAL_INVESTIGATORMatthieu Legrand, M.D., Ph.D
University of California, San Francisco
Outcome results
None listed